Evaluation of a new APTIMA specimen collection and transportation kit for high-risk human papillomavirus E6/E7 messenger RNA in cervical and vaginal samples

Sexually Transmitted Diseases

Volumn 41, Issue 6, 2014, Pages 365-368

  Chernesky, Max ^a   Jang, Dan ^a   Gilchrist, Jodi ^a   Elit, Laurie ^b   Lytwyn, Alice ^b   Smieja, Marek ^a   Dockter, Janel ^c,d   Getman, Damon ^c,d   Reid, Jennifer ^c,d   Hill, Craig ^c,d  

^a MCMASTER UNIVERSITY   (Canada)

^b HAMILTON HEALTH SCIENCES   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d Gen Probe Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; DIAGNOSTIC KIT; VIRUS RNA;

ADULT; ARTICLE; COLPOSCOPY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HIV RAPID TEST; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MIDDLE AGED; PAPILLOMAVIRUS INFECTION; SELF CONCEPT; SENSITIVITY AND SPECIFICITY; VAGINA SMEAR KIT; YOUNG ADULT; ADOLESCENT; COMPARATIVE STUDY; DIAGNOSTIC KIT; EVALUATION STUDY; GENETICS; ISOLATION AND PURIFICATION; LABORATORY DIAGNOSIS; PAPILLOMA VIRUS; PATHOLOGY; PROCEDURES; REPRODUCIBILITY; SELF CARE; UTERINE CERVIX; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX TUMOR; VAGINA SMEAR; VIROLOGY;

ADOLESCENT; ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; COLPOSCOPY; FEMALE; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; REAGENT KITS, DIAGNOSTIC; REPRODUCIBILITY OF RESULTS; RNA, MESSENGER; RNA, VIRAL; SELF CARE; SENSITIVITY AND SPECIFICITY; SPECIMEN HANDLING; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 84901255752     PISSN: 01485717     EISSN: 15374521     Source Type: Journal    
DOI: 10.1097/OLQ.0000000000000125     Document Type: Article

References (30)

1. zur Hausen H. Papillomavirus in the causation of human cancersVA brief historical account. Virology 2009; 348:260-265.
2. Naucler P, Ryd W, Törnberg S, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007; 357:1589-1597.
3. Mayrand MH, Duarte-Franco E, Rodrigues I, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007; 357:1579-1588.
4. Arbyn M, Verdoodt F, Snijders PJF, et al. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: A meta-analysis. Lancet Oncol 2014; 15:172-183.
5. Getman D, Aiyer A, Dockter J, et al. Efficiency of the APTIMA HPV assay for the detection of HPV RNA and DNA targets. J Clin Virol 2009; 45:S49-54.
6. Dockter J, Schroder A, Eaton B, et al. Analytical characterization of the APTIMA assay. J Clin Virol 2009; 45:S39-47.
7. Dockter J, Schroder A, Hill C, et al. Clinical performance of the APTIMA HPV assay for the detection of high-risk HPV and highgrade cervical lesions. J Clin Virol 2009; 45:S55-61.
8. Szarewski A, Mesher D, Cadman L, et al. Comparison of seven tests for high-grade cervical intraepithelial neoplasia in women with abnormal smears: The Predictors 2 Study. J Clin Micro 2012; 50: 1867-1873.
9. Clad A, Reuschenbach M, Weinschenk J, et al. Performance of the APTIMA high-risk human papillomavirus mRNA assay in a referral population in comparison with hybrid capture 2 and cytology. J Clin Micro 2011; 49:1071-1076.
10. Ratnam S, Coutlee F, Fontaine D, et al. APTIMA HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 Assay but more specific at detecting cervical precancer and cancer. J Clin Micro 2011; 49:557-564.
11. Monsonego J, Hudgens MG, Zerat L, et al. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: The FASE study. Int J Cancer 2011; 129:691-701.
12. Monsonego J, Hudgens M, Zerat L, et al. Risk assessment and clinical impact of liquid-based cytology, oncogenic human papillomavirus (HPV) DNA and mRNA testing in primary cervical cancer screening (The FASE Study). J Gynecol Oncol 2012; 125:175-180.
13. Cuzick, J, Cadman, L, Mesher, D, et al. Comparing the performance of six human papillomavirus tests in a screen population. Br J Cancer 2012; doi:10.1038/bjc.2013.22
14. Chernesky M, Huang S, Jang D, et al. Performance of a new HPV cervi-collect collection and transportation kit. J Oncol 2012; 503432.
15. Gustavsson I, Sanner K, Lindell M, et al. Type specific detection of high-risk human papillomavirus (HPV) in self-sampled cervicovaginal cells applied to FTA Elute Cartridge. J Clin Virol 2011; 51:255-258.
16. Petignat P, Hankins C, Walmsley S, et al. Self-sampling is associated with increased detection of human papillomavirus DNA in the genital tract of HIV-seropostive women. Clin Infect Dis 2005; 41:527-534.
17. Sellors JW, Lorincz, AT, Mahony JB, et al. Comparison of selfcollected vaginal, vulvar and urine samples with physician-collected cervical samples for human papillomavirus testing to detect high-grade squamous intraepithelial lesions. Can Med Assoc J 2000; 163:513-518.
18. Gage JC, Partridge EE, Rausa A, et al. Comparative performance of human papillomavirus dna testing using novel sample collection methods. J Clin Microbiol 2011; 49:4185-4189.
19. CherneskyM, Jang D, Portillo E, et al. Comparison of three assays for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae in SurePath samples and the role of pre-and post-cytology testing. J Clin Microbiol 2012; 50:1281-1284.
20. Horvath C, Boulet G, Sahebali S, et al. Effects of fixation on RNA integrity in a liquid-based cervical cytology setting. J Clin Pathol 2008; 61:132-137.
21. Powell N, Smith K, Fiander A. Recovery of human papillomavirus nucleic acids from liquid-based cytology media. J Virol Methods 2006; 137:58-62.
22. Chernesky M, Gilchrist J, Jang D, et al. Effect of proteinase K treatment of SurePath L-Pap samples on detection of HPV mRNA. Eurogin International Multidisciplinary Congress Meeting; 2012; Prague, Czech Republic.
23. Belinson JL, Hu S, Niyazi M, et al. Prevalence of type-specific human papillomavirus in endocervical, upper and lower vaginal, perianal and vaginal self-collected specimens; implications for vaginal self-collection. Int J Cancer 2010; 127:1151-1157.
24. Belinson J, Du H, Yang B, et al. Improved sensitivity of vaginal selfcollection and high-risk human papillomavirus testing. Int J Cancer 2011; 130:1855-1860.
25. Dzuba IG, D́az EY, Allen B, et al. The acceptability of self-collected samples for HPV testing vs. The Pap test as alternatives in cervical cancer screening. J Womens Health Gend-Based Med 2002; 11:265-275.
26. Newman SB, Nelson MB, Gaydos CA, et al. Female prisoners'preferences of collection methods for testing Chlamydia trachomatis and Neisseria gonorrhoeae infection. Sex Transm Dis 2003; 30:306-309.
27. Chernesky M, Hook E, Martin D, et al. Women find it easy and prefer to collect their own vaginal swabs to diagnose Chlamydia trachomatis and Neisseria gonorrhoeae infections. Sex Transm Dis 2005; 32:729-733.
28. Tisci S, Shen YH, Fife D, et al. Patient acceptance of self-sampling for human papillomavirus in rural China. J Low Genit Tract Dis 2003; 7:107-116.
29. Anhang R, Nelson JA, Telerant R, et al. Acceptability of selfcollection of specimens for HPV DNA testing in an urban population. J Womens Health 2005; 14:721-728.
30. Kahn JA, Bernstein DI, Rosenthal SL, et al. Acceptability of human papillomavirus self-testing in female adolescents. Sex Transm Infect 2005; 81:408-414.